866-997-4948(US-Canada Toll Free)

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 140 Pages

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H2 2016, provides in depth analysis on Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) Overview 10
Therapeutics Development 11
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Stage of Development 11
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Therapy Area 12
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Indication 13
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Companies 17
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Universities/Institutes 25
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Therapeutics Assessment 27
Assessment by Monotherapy/Combination Products 27
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 34
Advenchen Laboratories, LLC 34
Amgen Inc. 35
ArQule, Inc. 36
Astellas Pharma Inc. 37
AstraZeneca Plc 38
AVEO Pharmaceuticals, Inc. 39
Batu Biologics, Inc. 40
Bayer AG 41
Boehringer Ingelheim GmbH 42
Bristol-Myers Squibb Company 43
Celon Pharma Sp. z o.o. 44
Daiichi Sankyo Company, Limited 45
Debiopharm International SA 46
Eddingpharm 47
Eisai Co., Ltd. 48
Eli Lilly and Company 50
Hutchison MediPharma Limited 51
Incyte Corporation 52
Johnson & Johnson 53
Kaken Pharmaceutical Co., Ltd. 54
Les Laboratoires Servier SAS 55
Nobelpharma Co., Ltd. 56
Novartis AG 57
Principia Biopharma Inc. 58
Vichem Chemie Research Ltd. 59
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Drug Profiles 60
ARQ-087 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
ASP-5878 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
AZD-4547 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
BAY-1163877 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
BAY-1179470 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
BMS-986036 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
CPL-043 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Debio-1347 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
DS-1123 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
E-7090 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
EDP-317 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
erdafitinib - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
GP-369 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
HMPL-453 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
INCB-54828 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
infigratinib - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
L-27 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
lenvatinib mesylate - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
lucitanib - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
LY-2874455 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
nintedanib - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
palifermin - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
PRN-1371 - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
RPT-835 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
S-49076 - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
trafermin - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
trafermin - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
Vallovax - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Dormant Projects 119
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Discontinued Products 122
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Featured News & Press Releases 124
Oct 26, 2016: Eisais LENVIMA (lenvatinib) Nominated for Galien Foundations Best Pharmaceutical Product 124
Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST 124
Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 125
Oct 09, 2016: ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung 127
Oct 09, 2016: People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima (lenvatinib) in Scotland 128
Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 130
Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders 130
Sep 30, 2016: Eisai To Initiate Phase III Clinical Study Of Anticancer Agent Lenvatinib As Potential First-Line Therapy For Advanced Renal Cell Carcinoma 131
Sep 29, 2016: Eisai To Present Latest Data On Lenvatinib At ESMO Congress 2016 132
Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress 133
Sep 21, 2016: Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association 134
Sep 15, 2016: Eisai Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 135
Sep 15, 2016: ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal 136
Sep 09, 2016: Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease 136
Sep 07, 2016: New long-term data demonstrates continued safety and beneficial effect of OFEV (nintedanib) for patients with IPF 137
Appendix 139
Methodology 139
Coverage 139
Secondary Research 139
Primary Research 139
Expert Panel Validation 139
Contact Us 139
Disclaimer 140

List of Tables
Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Indication, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Development by Companies, H2 2016 (Contd..2) 20
Products under Development by Companies, H2 2016 (Contd..3) 21
Products under Development by Companies, H2 2016 (Contd..4) 22
Products under Development by Companies, H2 2016 (Contd..5) 23
Products under Development by Companies, H2 2016 (Contd..6) 24
Number of Products under Investigation by Universities/Institutes, H2 2016 25
Products under Investigation by Universities/Institutes, H2 2016 26
Assessment by Monotherapy/Combination Products, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Pipeline by Advenchen Laboratories, LLC, H2 2016 34
Pipeline by Amgen Inc., H2 2016 35
Pipeline by ArQule, Inc., H2 2016 36
Pipeline by Astellas Pharma Inc., H2 2016 37
Pipeline by AstraZeneca Plc, H2 2016 38
Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 39
Pipeline by Batu Biologics, Inc., H2 2016 40
Pipeline by Bayer AG, H2 2016 41
Pipeline by Boehringer Ingelheim GmbH, H2 2016 42
Pipeline by Bristol-Myers Squibb Company, H2 2016 43
Pipeline by Celon Pharma Sp. z o.o., H2 2016 44
Pipeline by Daiichi Sankyo Company, Limited, H2 2016 45
Pipeline by Debiopharm International SA, H2 2016 46
Pipeline by Eddingpharm, H2 2016 47
Pipeline by Eisai Co., Ltd., H2 2016 48
Pipeline by Eli Lilly and Company, H2 2016 50
Pipeline by Hutchison MediPharma Limited, H2 2016 51
Pipeline by Incyte Corporation, H2 2016 52
Pipeline by Johnson & Johnson, H2 2016 53
Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016 54
Pipeline by Les Laboratoires Servier SAS, H2 2016 55
Pipeline by Nobelpharma Co., Ltd., H2 2016 56
Pipeline by Novartis AG, H2 2016 57
Pipeline by Principia Biopharma Inc., H2 2016 58
Pipeline by Vichem Chemie Research Ltd., H2 2016 59
Dormant Projects, H2 2016 119
Dormant Projects (Contd..1), H2 2016 120
Dormant Projects (Contd..2), H2 2016 121
Discontinued Products, H2 2016 122
Discontinued Products (Contd..1), H2 2016 123

List of Figures
Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Top 10 Indication, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 27
Number of Products by Mechanism of Actions, H2 2016 28
Number of Products by Stage and Mechanism of Actions, H2 2016 28
Number of Products by Routes of Administration, H2 2016 30
Number of Products by Stage and Routes of Administration, H2 2016 30
Number of Products by Molecule Types, H2 2016 32
Number of Products by Stage and Molecule Type, H2 2016 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *